Investing RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Prev Post Completion of Tranche 1 of the Placement December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts Torchlight Innovations Inc.Opens the Market October 25, 2025 Thor Energy Plans to Recover Uranium, Critical Minerals from Colorado Mine Waste October 25, 2025 Quimbaya Gold Announces Upsize of Bought Deal Financing to $12.5 Million October 25, 2025
